Search

Displaying results 2101 - 2110 of 10000 in total
  1. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    [L8237] This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213] … [A184067] This region of the brain is highly involved in motor control.[A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.

  2. Drug

    Lurasidone

    go.drugbank.com/drugs/DB08815
    ApprovedInvestigational

    Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.

  3. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … [A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy.

  4. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [L51083] Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body. … [A264108] The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory

  5. Drug

    Tapinarof

    go.drugbank.com/drugs/DB06083
    ApprovedInvestigational

    Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. … [A248790] Tapinarof received initial approval from the FDA in 2022.[L41845]

  6. Drug

    SIG-001

    go.drugbank.com/drugs/DB17826
    Investigational

    SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer

  7. Drug

    Valrubicin

    go.drugbank.com/drugs/DB00385
    Approved

    It is a semisynthetic analog of the [doxorubicin], which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder. … Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR.

    Categories: Topoisomerase II Inhibitors
  8. Drug

    Velmanase alfa

    go.drugbank.com/drugs/DB12374
    ApprovedInvestigational

    [L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment … [A244509] In February 2023, the FDA also approved velmanase alfa for the same indication.[L45295] Velmanase alfa is currently not approved in Canada.

  9. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893] … [L43642] Eladocagene exuparvovec received EMA approval in July 2022.

  10. Drug

    Clascoterone

    go.drugbank.com/drugs/DB12499
    ApprovedInvestigational

    [A218846] In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older. … Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity.